The FDA approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in adults with complement 3 glomerulopathy ...

Sponsor: Kidneys for Communities Kidney disease is one of the leading causes of death in America, with nearly 100,000 people ...

Advanced treatments for kidney failure offers patients improved survival rates and quality of life. Discover the options from ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

John and his wife, Rachel Meadows, are sharing more about their search. The happy couple has twin 3-year-old boys, they say ...

Discover these kidney-friendly superfoods that can help manage symptoms, provide essential nutrients, and add delicious ...

A new study led by Dr. Hilla Chen from the Koret School of Veterinary Medicine at Hebrew University, recently published in ...

The study, published in the Journal of Veterinary Internal Medicine, examined the effects of paricalcitol -- a synthetic form ...

According to the CDC, around 37 million American adults have chronic kidney disease, and millions more are at risk of developing it.

In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization, a ...

Addressing patients with chronic kidney disease requires a commitment to data, education, and community, specifically in those affected by social determinants of health (SDOH).

A new study led by Dr. Hilla Chen, Prof. Gilad Segev and Dr. Michal Mazaki-Tovi from the Koret School of Veterinary Medicine ...